Guide for COVID-19 Response in Kenya
Reporting period: January 2008-December 2010
Accessed: 29.09.2019
Training for staff working at DR-TB management centres.
Training modules
AIDS 2024, 38:1579–1588. Treatment interruptions are a barrier to successful antiretroviral therapy (ART). 'Fresh start messages', which leverage significant days on the calendar (e.g., new year, public holiday) in order to prompt action, have the potential to encourage people with HIV (PWH) to re...turn to care. We evaluated a 'fresh start' intervention (text messages) to increase return to care in PWH who had missed their last appointment.
more
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more
Web annex 6: Injectable prostaglandins versus
placebo or no treatment
Evidence to Decision Framework
Diploma Program
For the Ethiopian Health Center Team
Cornerstone of our society
special education, culture, psychology, education, policy
Web annex 2: Carbetocin versus placebo or no treatment
Evidence to decision framework